title: Using direct-to-consumer marketing strategies with obsessive-compulsive disorder in the nonprofit sector.
abstract: Three to four million individuals struggle with obsessive-compulsive disorder (OCD) in the United States at any given time. OCD can be a debilitating disorder associated with significant quality-of-life and occupational impairment. First-line treatments for OCD (selective serotonin reuptake inhibitors and exposure and response prevention therapy) have been shown to be effective; yet, many individuals suffering from OCD experience multiple barriers to accessing these treatments. In fact, it can take as many as 17 years from onset of symptoms to effective treatment. Given the need to increase access to and utilization of effective treatments, direct-to-consumer marketing in the context of OCD appears crucial. The International OCD Foundation (formerly the Obsessive Compulsive Foundation) was established as a nonprofit organization with a mission to educate the public and mental health professionals about appropriate practice guidelines, raise awareness of the disorder, and ensure that individuals looking for treatment find the necessary resources. This paper reviews the obstacles those struggling with OCD face in their attempts to alleviate suffering, as well as the direct-to-consumer strategies and tactics used by the International OCD Foundation to improve access to empirically supported, effective treatment.
authors.affiliation: International OCD Foundation, Inc., 112 Water Street, #501, Boston, MA 02109, USA. jszymanski@ocfoundation.org
authors.forename: Jeff
authors.initials: J
authors.lastname: Szymanski
mesh_terms: D019317:Evidence-Based Medicine; D006801:Humans; D008389:Marketing of Health Services; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy* / Q000523:psychology; D009939:Organizations, Nonprofit; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D016896:Treatment Outcome; D014481:United States
chemical_list: D017367:Selective Serotonin Reuptake Inhibitors